RT15

RT15 is a triple receptor agonist targeting GLP‑1, GIP and glucagon receptors, with four primary therapeutic effects:

1. Glycemic regulation
   It boosts glucose-dependent insulin secretion and restrains excess glucagon release to stabilize blood glucose levels, lower glycated hemoglobin and relieve insulin resistance in type 2 diabetes, with a low risk of hypoglycemia.
2. Weight and visceral fat reduction
   The triple synergistic pathway accelerates fat breakdown and resting metabolism. It preferentially burns visceral fat and delivers superior weight loss results while preserving lean muscle mass.
3. Appetite suppression
   It delays gastric emptying and acts on the hypothalamic satiety center to sustainably reduce hunger and cravings for high-calorie food, naturally cutting daily calorie intake for long-term weight management.
4. Comprehensive metabolic improvement
   It optimizes lipid profiles, alleviates hypertension and obesity-related sleep apnea, and relieves metabolic complications including non-alcoholic fatty liver disease and PCOS. It also shows potential cardiorenal protective benefits.